Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 5/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | PPARA | Q07869 | 2/20 | 0.38 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.38 |
| ▸ | PDE11A | Q9HCR9 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | PPARG | P37231 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | GFER | P55789 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8286548 | 0.91 | SMN1; SMN2 (0.50) | GAAPOLBSMN1; SMN2NPC1RAB9A | |
| SCHEMBL8286039 | 0.90 | ALDH1A1 (0.43) | POLBSMN1; SMN2HPGDHSD17B10KMT2A | |
| SCHEMBL7036674 | 0.89 | ALDH1A1 (0.41) | GAASMN1; SMN2ABCB1PDE11AHPGD | |
| SCHEMBL5872280 | 0.87 | ALDH1A1 (0.46) | GAASMN1; SMN2KDM4EKMT2ARXFP1 | |
| SCHEMBL8287221 | 0.87 | APLNR (0.42) | GAASMN1; SMN2ABCB1PDE11AHPGD | |
| SCHEMBL8285337 | 0.86 | HSP90AA1 (0.47) | GAAPOLBSMN1; SMN2PDE11AHPGD | |
| SCHEMBL8287549 | 0.83 | PDE11A (0.39) | GAASMN1; SMN2NPC1RAB9APDE11A | |
| SCHEMBL7046873 | 0.83 | PDE11A (0.37) | GAAPOLBSMN1; SMN2NPC1RAB9A | |
| SCHEMBL5871665 | 0.83 | GAA (0.36) | GAAPOLBPPARAABCB1PDE11A | |
| SCHEMBL8361765 | 0.82 | GAA (0.45) | GAAPOLBSMN1; SMN2PPARAPDE11A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7109196-B2 | 1,8 Naphthyridine derivatives and their use to treat diabetes and related disorders | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-09-19 | — | — | US | disclosed |
| US-20060189609-A1 | 1, 8-Naphthyridine derivatives and their use to treat diabetes and related disorders | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-08-24 | — | — | US | disclosed |
| US-6964971-B2 | 1,6-naphthyridine derivatives and their use to treat diabetes and related disorders | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-11-15 | — | — | US | disclosed |
| WO-2005091857-A2 | 1,6-NAPHTHYRIDINE AND 1,8-NAPHTHYRIDINE DERIVATIVES AND THEIR USE TO TREAT DIABETES AND RELATED DISORDERS | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-10-06 | — | — | WO | disclosed |
| WO-2005091857-A2 | 1,6-NAPHTHYRIDINE AND 1,8-NAPHTHYRIDINE DERIVATIVES AND THEIR USE TO TREAT DIABETES AND RELATED DISORDERS | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-10-06 | — | — | WO | disclosed |
| WO-2005051380-A1 | SUBSTITUTED UREA-OCTAHYDROINDOLS AS ANTAGONISTS OF MELANIN CONCENTRATING HORMONE RECEPTOR 1 (MCH1R) | BIOVITRUM AB (SE) | 2005-06-09 | — | — | WO | disclosed |
| US-6900205-B2 | 1,8-Naphthyridine derivatives and their use to treat diabetes and related disorders | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-05-31 | — | — | US | disclosed |
| US-20040209866-A1 | 1,8 Naphthyridine derivatives and their use to treat diabetes and related disorders | BAYER PHARMACEUTICALS CORPORATION | 2004-10-21 | — | — | US | disclosed |
| US-20040157875-A1 | 1, 6-Naphthyridine derivatives and their use to treat diabetes and related disorders | BAYER PHARMACEUTICALS CORPORATION | 2004-08-12 | — | — | US | disclosed |
| EP-1432710-A1 | 1, 8-NAPHTHYRIDINE DERIVATIVES AS ANTIDIABETICS | Bayer Pharmaceuticals Corporation (US) | 2004-06-30 | — | — | EP | disclosed |
| EP-1432711-A1 | 1,6-NAPHTHYRIDINE DERIVATIVES AS ANTIDIABETICS | Bayer Corporation (US) | 2004-06-30 | — | — | EP | disclosed |
| US-20040014751-A1 | 1,8-Naphthyridine derivatives and their use to treat diabetes and related disorders | BAYER CORPORATION | 2004-01-22 | — | — | US | disclosed |
| US-6677352-B1 | 1,6-naphthyridine derivatives and their use to treat diabetes and related disorders | BAYER PHARMACEUTICALS CORPORATION | 2004-01-13 | — | — | US | disclosed |
| WO-2003027112-A1 | 1, 8-NAPHTHYRIDINE DERIVATIVES AS ANTIDIABETICS | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-04-03 | — | — | WO | disclosed |
| WO-2003027113-A1 | 1,6-NAPHTHYRIDINE DERIVATIVES AS ANTIDIABETICS | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-04-03 | — | — | WO | disclosed |
| WO-2003027112-A1 | 1, 8-NAPHTHYRIDINE DERIVATIVES AS ANTIDIABETICS | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040157875-A1 | 1, 6-Naphthyridine derivatives and their use to treat diabetes and related disorders | GLP1R, NQO1, UQCRC1 | GAA 458/4885POLB 2295/4885SMN1; SMN2 2827/4885 |
| US-20040209866-A1 | 1,8 Naphthyridine derivatives and their use to treat diabetes and related disorders | SLC5A1, NQO1, GLP1R | GAA 422/4885POLB 1864/4885SMN1; SMN2 2937/4885 |
| US-20040014751-A1 | 1,8-Naphthyridine derivatives and their use to treat diabetes and related disorders | UQCRC1, GLP1R, SLC5A1 | GAA 375/4885POLB 1560/4885SMN1; SMN2 3159/4885 |
| US-20060189609-A1 | 1, 8-Naphthyridine derivatives and their use to treat diabetes and related disorders | GLP1R, UQCRC1, SLC5A1 | GAA 415/4885POLB 1491/4885SMN1; SMN2 3149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.